Aller au contenu principal
Accès ouvert déclaré 2025 article

The PSMA-PET Conundrum: A Survey of UK Prostate Cancer Surgeons and Their Use of PSMA-PET Prior to Radical Prostatectomy

0Citations signalées — pas une note de qualité
1Institutions déclarées
1Pays d’affiliation déclarés

Résumé fourni par la source

Objectives: Prostate-specific membrane antigen-positron emission tomography (PSMA-PET) has significantly improved sensitivity and specificity for detecting metastatic disease in prostate cancer compared to traditional computed tomography and bone scans. It is now recommended by the European Association of Urology for staging intermediate and high-risk disease, however, there are no recommendations on its incorporation into practice due to lack of long-term survival data. We aimed to identify the current use of PSMA-PET in high-volume prostate cancer centres to see whether there is standardisation in its use and interpretation prior to robotic-assisted laparoscopic prostatectomy (RALP). Methods: was sent to multiple high-volume surgeons across the United Kingdom (UK), with all questions optional. Participants were asked about their personal practices for PSMA-PET staging, for both intermediate and high-risk disease, and how it would change their management if considering RALP. Results: Thirty-one participants responded across 17 different UK centres. 11/31 (35%) used PSMA-PET a lone as primary staging for high-risk prostate cancer, with 6/30 (20%) using it for intermediate staging as well. Of the 23 surgeons that routinely perform lymph node dissection (LND) in high-risk cases, 13/23 (57%) would obviate performing it if the PSMA was negative. If a patient was found to have positive nodes on PSMA-PET, 12/31 (39%) surgeons will still offer RALP. Individual answers also varied within same centres. Conclusion: The current interpretation of PSMA-PET for staging and treatment before RALP varies widely amongst surgeons, particularly regarding LND. A national consensus statement is needed to help standardise treatment practice for patients until robust long-term survival data exists.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref
The PSMA-PET Conundrum: A Survey of UK Prostate Cancer Surgeons and Their Use of PSMA-PET Prior to Radical Prostatectomy
Date Crossref
08/10/2025
Éditeur
Galenos Yayinevi
Type
journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude et ne compte pas comme une seconde source scientifique indépendante.

Institutions déclarées

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Sujets associés

Prostate Cancer Diagnosis and TreatmentProstate Cancer Treatment and ResearchUrinary Bladder and Prostate Research

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.